Sure. I will do it in two slides.
In this first slide, if you compare the revision rate or the re-operation of patients in the U.S.A. versus Sweden, you can see that the Swedish action taken on the introduction of new technology was very effective, and I would say in Europe there is a broad change to move forward with the evolution of new technology, including precision technology.
I conclude by saying that the introduction of new devices is driven by the industry and its financial benefit. New device introduction in the Canadian health care system should follow a similar path as drug introduction, and clear rules should be determined to protect patient health and reduce costs.
Thank you.